Lazard Asset Management
RVMD icon

Lazard Asset Management’s Revolution Medicines RVMD Stock Holding History

Lazard Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,380
Closed -$51K – 2506
2023
Q1 		$51K Buy
+2,380
New +$58.6K ﹤0.01% 1791

Other funds holding RVMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Lazard Asset Management's RVMD Position: Q2 2023 in Review

Lazard Asset Management sold out of Revolution Medicines (RVMD) in Q2 2023, closing a stake of 2,380 shares — an estimated $51K sold.

Lazard Asset Management first reported a position in RVMD in Q1 2023 and held it in 1 quarter. The position peaked at $51K in Q1 2023. 139 funds tracked by Wall St. Rank hold RVMD as of Q2 2023.

  • Lazard Asset Management reported no remaining Revolution Medicines position as of Q2 2023 after selling out during the quarter.
  • Lazard Asset Management sold 2,380 Revolution Medicines shares in Q2 2023, an estimated $51K.
  • Lazard Asset Management first reported a position in Revolution Medicines in Q1 2023 and held it in 1 quarter.
  • Lazard Asset Management's Revolution Medicines position peaked at $51K in Q1 2023.
  • 139 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2023.

Based on Lazard Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.